Roundtable Discussion: Late-Stage Clinical to Post-Approval Planning

Time: 11:15 am
day: Day 2 Track B AM

Details:

  • How will drug scheduling impact manufacturing and what roadblocks can be mitigated?
  • What safety profiles must be demonstrated and what are the biggest concerns
  •  What do the insurers anticipate will be the pattern of renumeration?

Speakers: